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ALS is a devastating neurodegenerative disease characterized by progres-
sive paralysis and respiratory failure leading to death. Much attention 
has focused on the discovery of causal genes on the basis that under-
standing the pathophysiology underlying motor neuron degeneration 
would provide rational targets for therapeutic development. The genetic 
etiology of two-thirds of the familial form of ALS and 11% of the more 
common sporadic form of the disease are now known1. Nevertheless, 
the discovery of more genes would allow more complete mapping of 
the cellular pathways underlying this condition.
Here we applied exome sequencing to a family of European ances-
try in which several individuals had been diagnosed with ALS and 
dementia (Fig. 1a) with the aim of identifying the causative muta-
tion. We found two previously unknown, heterozygous missense vari-
ants that segregated with disease in this kindred, namely Ala436Val 
(chr5:126156748, C>T) in LMNB1 and Phe115Cys (chr5:138643448, 
T >G) in MATR3. Neither variant was present in population polymor-
phism databases (including the Exome Sequencing Project (n = 13,000 
control chromosomes), the 1000 Genomes Project (n = 2,184 chro-
mosomes) and dbSNP) or in the Human Gene Diversity Panel 
(n = 2,102 chromosomes screened in our laboratory). The MATR3 
variant was also not present in another 5,190 neurologically normal 
subjects genotyped in our laboratory, bringing the total number of 
control chromosomes that did not carry this transversion to 27,666.
A Ser85Cys (chr5:138643358, C>G) mutation in MATR3 was previ-
ously reported as the cause of autosomal dominant, distal, asymmetri-
cal myopathy with vocal cord paralysis in a large, multigenerational 
family (Fig. 1b)2,3. Neurophysiological studies and muscle biopsies of 
affected members were variably reported to be consistent with either 
a neurogenic or a myopathic pattern.
In light of our genetic findings, the senior author (B.J.T.) and the 
neurologist who initially reported this family (H.F.) reevaluated the 
Ser85Cys MATR3 family. Affected individuals developed progressive 
respiratory failure resulting in death, typically after 15 years of illness. 
Pathologically brisk knee reflexes, indicative of upper motor neuron 
lesions, were present in four of six patients examined. One patient 
also had brisk upper limb reflexes, as well as tongue fasciculations 
and a brisk jaw jerk. All of the examined cases displayed a ‘split-hand’ 
pattern of weakness suggestive of a lesion in the anterior horn of the 
cervical spinal cord, a sign commonly observed in ALS patients4. 
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MATR3 is an RNA- and DNA-binding protein that interacts 
with TDP-43, a disease protein linked to amyotrophic lateral 
sclerosis (ALS) and frontotemporal dementia. Using exome 
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provide more evidence supporting the role of aberrant RNA 
processing in motor neuron degeneration.
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These clinical findings supported reclassification of this condition as 
slowly progressive ALS, and the presence of upper motor neuron signs 
in the form of brisk reflexes ruled out myopathy as the only cause of 
disease in this family.
To determine the frequency of MATR3 mutations as a cause of 
ALS, we examined exome sequence data from 108 additional familial 
ALS cases. We identified a Thr622Ala (chr5:138658372, A>G) missense 
change in MATR3 in a 66-year-old Sardinian diagnosed with familial 
ALS. This variant was present in a first cousin, who had also presented 
with typical, rapidly progressive ALS at the age of 64 (Fig. 1c). In addi-
tion, custom resequencing of genes linked to neurodegeneration in 
96 British ALS cases identified a Pro154Ser (chr5:138643564, C>T) 
missense variant in MATR3 in an individual diagnosed with sporadic 
disease (Fig. 1d and Supplementary Fig. 1). 
Again, neither mutation was present in pop-
ulation polymorphism databases or in the 
Human Gene Diversity Panel (n = 17,286 con-
trol chromosomes). More studies are required 
to confirm the pathogenicity of these vari-
ants, especially Pro154Ser, which was found 
in a single sporadic case and consequently 
lacks segregation data. We did not find any 
more mutations in the LMNB1 gene.
We examined subcellular distribution 
of MATR3 using immunohistochemistry. 
In control subjects, we detected MATR3 in 
a granular staining pattern in the nuclei of 
motor neurons and surrounding glial cells 
(Supplementary Fig. 2a). In ALS patients, 
we observed MATR3 in the nuclei of remain-
ing motor neurons and occasionally in the 
cytoplasm (Supplementary Fig. 2b). In a 
patient harboring the Phe115Cys MATR3 
mutation, MATR3 immunoreactivity was 
intense in the nucleus of all motor neurons 
and diffuse cytoplasmic staining was evident 
in many neurons (Supplementary Fig. 2c). Cytoplasmic inclusions 
were absent in this individual. However, we detected rare MATR3-
positive cytoplasmic inclusions in an ALS patient known to carry the 
C9ORF72 repeat expansion (Supplementary Fig. 3).
MATR3 is a 125-kDa nuclear matrix protein that binds DNA 
and RNA. Previous unbiased screens found that MATR3 protein 
interacts with TDP-43, an RNA-binding protein whose mutation is 
known to cause ALS5,6. To confirm this interaction, we performed 
coimmunoprecipitation of Flag-tagged MATR3 variants with 
endogenous TDP-43 in human embryonal kidney cells transformed 
with the SV40 large T antigen (HEK293FT cells). As the genetic 
data were strongest for the Phe115Cys and Ser85Cys mutations, we 
selected these variants for further scrutiny, as well as the Thr622Ala 
Figure 1 Pedigrees of patients with MATR3 mutations. (a) Kindred USALS#3. (b) Kindred. (c) Kindred ITALS#10. (d) Kindred UKALS#1. mt, mutant 
alleles; wt, wild-type alleles3. Genotypes of presumed obligate carriers are in brackets. Red asterisks indicate individuals who underwent clinical 
examination. Arrows denote probands.
Figure 2 Immunoprecipitation of MATR3 with TDP-43. (a) Flag-MATR3 was expressed in HEK293FT 
cells, immunoprecipitated using anti-Flag antibody and probed with TDP-43 and DHX9 antibodies. 
Untransfected cells, Mock; cells transfected with wild-type Flag-MATR3 construct, WT; cells transfected 
with Flag-MATR3 construct carrying the Ser85Cys mutation, S85C; carrying the Phe115Cys mutation, 
F115C; carrying the Thr622Ala mutation, T622A. Molecular weight (in kDa) of protein marker is shown 
to the right of the blots. (b) Graphs show ratio of immunoprecipitated TDP-43 or DHX9 to Flag-MATR3; 
mean ± s.e.m. based on 10 replicate immunoprecipitation experiments. Differences in interaction 
between MATR3 and TDP-43 were tested with Wilcoxon signed rank test; **P < 0.01. Full-length blots 
are presented in Supplementary Figure 10.
USALS#3 (Phe115Cys)
I
a c d
b
III
II
1 2
1
USALS#4 (Ser85Cys)
1 2
21
I
III
II
7
2
mt/wt mt/wt
1 2–5 6
4
10
*
1–3 4–9
53
11 12,13
2IV
8,9
V
12
1 2
2–51
I
III
II
2
(mt/wt)
1
mt/wt
ITALS#10 (Thr622Ala)
4
6
3
mt/wt
4
4–7
1 2
I
III
II
UKALS#1 (Pro154Ser)
2–6
5
1
2
mt/wt
1
14 15 16
10 11
2
2 4 5
* * *
17,18
13–15 20
43
2
16–19 23
2
1
mt/wt
3
19,20 21 27
3 42
25 26
mt/wt mt/wt
4
28–3124
5
33
mt/wt
32
mt/wt
34
6 7
mt/wt
8
2
9,10
* *
11
35
12 13
mt/wt
14
2
15 16
mt/wt
36 37 38
21
22
22
23
mt/wt
(mt/wt)6 7 mt/wt
8,9 10 11
2
12–15
4
mt/wt mt/wt
2
6,7
3
1 2–5
mt/wt
4
(mt/wt)
Affected
Possibly affected
Affected by autism
a
150
100
75
50
37
150
100
75
50
37
150
50
37
Input IP: Flag
F
la
g-
G
F
P
W
T
S
85
C
F
11
5C
T
62
2A
M
oc
k
F
la
g-
G
F
P
W
T
S
85
C
F
11
5C
T
62
2A
M
oc
k
IB: Flag
(2% IP for
quantitation)
IB: Flag
IB: DHX9
IB: TDP-43
b
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0
W
T
S8
5C
F1
15
C
T6
22
A
MATR3 variants
(n = 10)
T
D
P
-4
3 
no
rm
al
iz
ed
 to
 M
AT
R
3 
IP
**
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0
W
T
S8
5C
F1
15
C
T6
22
A
MATR3 variants
(n = 10)
D
H
X
9 
no
rm
al
iz
ed
 to
 M
AT
R
3 
IP
np
g
© 
20
14
 N
at
ur
e A
m
er
ic
a,
 In
c.
 A
ll 
rig
ht
s 
re
se
rv
ed
.
666	 VOLUME 17 | NUMBER 5 | MAY 2014 nature neuroscience
B r i e f  com m u n i c at i o n s
variant, for which proof of pathogenicity was less clear. We found a 
reliable interaction that, interestingly, was increased by the Ser85Cys 
mutation but not by the Phe115Cys or Thr622Ala variants (Fig. 2). 
We also noted that Ser85Cys MATR3 was expressed at lower steady-
state levels than other variants, suggesting a structural effect of the 
mutation (Fig. 2). There was no alteration in interaction between 
MATR3 and a second protein interactor, DHX9, demonstrating that 
the effect of Ser85Cys is specific for TDP-43 and not generalized 
to all interactions of MATR3. Both interactions were abolished by 
RNase (Supplementary Fig. 4), demonstrating that they are RNA 
dependent. Coimmunoprecipitation of endogenous protein con-
firmed that MATR3 and TDP-43 interact at endogenous abundances 
(Supplementary Fig. 5). Also in accord with an interaction, MATR3 
and TDP-43 coaggregated in skeletal muscle tissue of a patient carry-
ing the Ser85Cys mutation (Supplementary Fig. 6).
Differential effects of different mutations in the same gene have 
been reported for other neurodegenerative diseases, such as famil-
ial Parkinson’s disease caused by LRRK2 mutations7 and familial 
ALS caused by FUS mutations8. Therefore, the lack of an effect of 
the Phe115Cys and Thr622Ala mutations on the MATR3–TDP-43 
interaction does not necessarily preclude their pathogenicity, as it 
is possible that these mutations disrupt other cellular processes in 
a manner that would not be detected by our assays. The variants 
found in MATR3 were distributed along the length of protein, per-
haps disrupting different nearby domains. Indeed, several functions 
have been associated with MATR3, including RNA processing6, 
retention of hyper-edited RNA9, gene silencing through interaction 
with Argonaute-containing complexes10, chromatin organization11  
and mediation of neuronal cell death in response to NMDA-type 
glutamate receptor activation12. The Ser85Cys variant only altered 
interaction with TDP-43 and not another MATR3 partner, DHX9. 
However, and reminiscent of mutations in VAPB13, Ser85Cys MATR3 
is notably less stable than other MATR3 variants. We infer that, of the 
genetic variants tested, Ser85Cys has the strongest effect on protein 
structure and that this is correlated with a change in affinity for 
TDP-43. The structural basis of this interaction will need to be 
resolved in future studies.
We note that the Ser85Cys mutation in MATR3 was associated 
with slowly progressive form of ALS, whereas individuals carrying 
the Phe115Cys-encoding mutation typically died from respiratory 
failure within 5 years of symptom onset. Similar phenotype variability 
has been observed for other ALS-associated genes. For example, the 
Ala4Val-encoding mutation of superoxide dismutase 1 is associated 
with an aggressive form of the disease with an average survival of 
only 9 months after symptom onset14. In contrast, the homozygous 
Asp90Ala-encoding mutation in the same gene is associated with an 
indolent course, with patients developing respiratory failure after 
10 years of illness14. Furthermore, the phenotype observed in some 
patients carrying MATR3 mutations combined features of ALS and 
myopathy. This clinical pattern is markedly similar to that observed 
in patients with mutations in VCP, HNRNPA1 and HNRNPA2B1, and 
the term “multisystem proteinopathy” has been used to reflect this 
broad pleiotropy15,16.
Exome sequencing data from the original family, as well as the 108 
familial ALS cases, have been made available on dbGaP (accession code 
phs000101). The public release of such data allows other ALS researchers 
around the world to access, reanalyze and combine it with their own 
sequence data, thereby accelerating the pace of gene discovery.
In summary, our genetic data identify mutations of the MATR3 gene 
as a rare cause of familial ALS and broaden the phenotype associated 
with this gene beyond the previously reported distal myopathy. This 
provides further insight into the importance of RNA metabolism in 
this fatal neurodegenerative disease.
MeThODS
Methods and any associated references are available in the online 
version of the paper.
Accession codes. dbGaP: phs000101.
Note: Any Supplementary Information and Source Data files are available in the 
online version of the paper.
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description of the USAlS#3 pedigree (Phe115cys). The proband (III:11, 
Fig. 1a) developed dysarthria at 50 years of age. He developed gait difficulties 
because of leg stiffness and cramping in the feet. He began choking on liquids at 
age 51 and developed pseudobulbar affect but no detectable cognitive impairment. 
Nocturnal noninvasive ventilation was prescribed for obstructive sleep apnea 
since age 53. Neurological examination at 52 years revealed mild, predominantly 
spastic dysarthria; increased jaw jerk; brisk facial reflexes, especially on the right; 
and slowed lateral tongue movements. Mild muscle atrophy was noted in the 
right thigh and rare fasciculations were seen in the proximal upper limbs. Tone 
was mildly spastic in the right arm and lower limbs, with slowed right fine finger 
movements and right foot tapping. Power in upper and lower limbs was normal. 
Tendon reflexes were pathologically brisk throughout, with right extensor plantar 
response. Gait and sensation were normal.
Dysarthria, dysphagia, and distal weakness in upper and lower extremities 
progressed slowly over 2 years, requiring use of bilateral ankle foot orthoses. 
Most recent neurologic examination at age 55 revealed mild cognitive impair-
ment with disinhibition and inability to vocalize (anarthria). Vertical saccades 
were slowed and upgaze was noticeably limited. Jaw jerk was markedly brisk 
with clonus, as were facial reflexes, and there was a hyperactive gag reflex. The 
tongue was severely atrophic, fasciculating, and unable to move off the midline 
or protrude beyond the lower teeth. Muscle atrophy was global, being moderate 
proximally and severe distally, especially in intrinsic hand muscles and forelegs. 
Fasciculations were active in both upper limbs and neck regions, and tone was 
markedly spastic in the arms and legs, particularly over the right side. Weakness 
was most prominent distally in hands and feet, with little or no movement of 
thumb and fingers (0–2/5) and ankle and toes (0–2/5). Proximal upper and 
lower limb strength was better (4/5), allowing the patient to stand, although 
shoulder pain from contractions limited useful arm function. Tendon reflexes 
were pathologically brisk throughout, more marked on the right with ipsilateral 
extensor plantar response. He was unable to walk because of the weakness and 
spasticity, and used a wheelchair for mobility.
Patient II:6. The mother of the proband (II:6, Fig. 1a) developed bilateral 
finger and hand weakness at age 70. This was followed a few months later 
by speech and swallowing problems, and ALS was diagnosed at age 71. Her 
father had died at 47 years of age after a prolonged course involving leg muscle 
weakness. Three siblings died in their eighties: one (II:1) died of dementia, 
another (II:2) developed limb weakness and was unable to walk at the time of 
death, and a third (II:5) died of dementia and also was reported to be dysarthric 
and to have upper limb weakness.
Neurological examination at 71 years revealed normal speech and cognition, 
brisk facial reflexes, mentalis muscle fasciculations and weak (4/5) neck flexors. 
Fasciculations were seen in both upper extremities and thighs, with moderate 
atrophy of intrinsic hand muscles. She was weaker distally, with thumb abduc-
tors, thumb flexors and intrinsic hand muscles 3/5, shoulder abductors 4/5, ankle 
dorsiflexors and toe extensors 4–/5, and hip flexors 4/5. Tendon reflexes were 
pathologically brisk, with a right extensor plantar response. Gait was unsteady 
and partially steppage in nature. Over the next 3 years, her limbs became pro-
gressively paralyzed and she developed dysarthria and mild cognitive impair-
ment. She died of respiratory failure at 75 years of age.
Patient II:7. An aunt of the proband (II:7, Fig. 1a) and identical twin of the 
proband’s mother developed slowly progressive hand weakness at 57 years of 
age. Four years later, she began experiencing dysarthria, at which point she was 
diagnosed with ALS. Her weakness gradually spread to the rest of her limbs and 
she developed severe cognitive impairment. Currently, at age 82, she is unable 
to stand or walk and uses a wheelchair for mobility. Her hand weakness has 
deteriorated to the point that she cannot feed herself or brush her teeth, and she 
is aphasic. She has respiratory failure (forced vital capacity 49%).
Patient III:10. The proband’s older sibling (III:10, Fig. 1a) developed right 
(dominant) hand stiffness and cramping at 52 years of age. At 57 years, he 
began experiencing progressive weakness of right hand and finger muscles 
resulting in inability to button or tie shoelaces. Atrophy of intrinsic right hand 
muscles was also noted. The patient denied leg weakness but would develop 
cramping of thigh muscles after squatting. About 18 months later the patient 
noticed worsening left hand weakness. There were no bulbar symptoms or short-
ness of breath initially.
Neurological examination at age 58 revealed no cognitive or behavioral 
abnormalities, normal speech, and no bulbar signs except for slightly increased 
right facial reflex and right palmomental reflex. Upper limbs showed moderate 
atrophy of distal muscles, especially of the lateral hand in a split hand pattern, 
with continuous fasciculation of right more than left shoulder and arm muscles. 
Lower limbs showed no changes. Tone was normal throughout. Weakness was 
most prominent distally and slightly worse on the right, with thumb abductors 
and deep finger flexors 3/5, finger abductors and extensors 4/5, wrist flexors 
and extensors 4+/5, and elbow flexors and extensors almost 5/5. Tendon reflexes 
were pathologically brisk throughout, with left extensor plantar response. Over 
the next 2 years, the patient’s condition gradually deteriorated, with progressive 
limb and respiratory muscle weakness. The patient expired 2 years later from 
respiratory failure at 60 years of age. Brain and spinal cord were obtained for 
pathologic analysis.
Patient III:1. A cousin of the proband (III:1, Fig. 1a) initially presented with 
lower limb weakness at 63 years of age. Symptoms progressed to involve the 
remaining limbs and bulbar musculature. Severe dysphagia necessitated the 
placement of a gastrostomy tube. The patient’s mother (II:3) died of dementia 
in her eighties. The patient became cognitively impaired several years after 
the initial presentation and died from respiratory failure at the age of 68.
Affected members of the USALS#3 kindred were negative for the pathogenic 
repeat expansion of C9ORF72.
description of the USAlS#4 pedigree (Ser85cys). The proband of the USALS#4 
family (IV:10, Fig. 1b) developed right foot drop at 44 years of age. Muscle weak-
ness spread to the remaining limbs over the next 2 years. A diagnosis of Charcot-
Marie-Tooth disease was made at the age 46 on the basis of a neurogenic pattern 
observed in an electromyogram and nerve conduction studies (EMG/NCS). 
Reevaluation 2 years later led to the patient’s illness being reclassified as non-
Scandinavian distal myopathy. The patient’s condition progressed, with the devel-
opment of dysarthria and mild dysphagia by the age of 53 and respiratory failure 
requiring nocturnal noninvasive ventilation by the age of 56. Currently, at age 65, 
the subject uses a power wheelchair for mobility.
Neurological examination at age 65 revealed mild dysarthria, perioral fascicu-
lations, a brisk jaw jerk and moderately weak neck extension. There was gener-
alized muscle wasting and pyramidal-distribution weakness in all four limbs. 
In the upper limbs, shoulder abduction was 3/5 bilaterally, elbow extension 
was 4/5, wrist extension and finger extension were 1/5, and finger abduction, 
finger adduction and thumb abduction were 3/5, whereas shoulder adduction, 
elbow flexion, wrist flexion and abductor digiti minimi were 5/5 bilaterally. In 
the lower limbs, hip flexion was 4/5 bilaterally; ankle dorsiflexion, ankle plantar 
flexion and extensor hallucis longus were 0/5, whereas hip abduction, hip adduc-
tion, knee flexion and knee extension were 5/5 bilaterally. Tendon reflexes were 
absent, and toes were mute on Babinski testing. Proprioception and vibration 
sensation were diminished to the level of the ankles and knees, respectively, 
bilaterally. The patient was able to stand and walk slowly using a walker and with 
the assistance of one person.
Patient V:2. A cousin of the proband (V:2, Fig. 1b) noticed right foot drop at 
42 years of age. Within 5 years, the muscle weakness had spread to involve 
both hands. The patient developed dysarthria and mild dysphagia at age 47 and 
respiratory failure requiring supplemental oxygen and noninvasive ventilation at 
49. The patient had an episode of aspiration pneumonia at age 55 that required 
prolonged intubation and ventilation. Currently, at age 57, the patient uses a 
power wheelchair but can walk slowly using a walker.
Neurological examination at age 57 revealed mild dysarthria, mild facial 
weakness, poor palate elevation and a brisk jaw jerk. Limb examination showed 
generalized muscle atrophy and a pyramidal pattern of weakness. In the upper 
limbs, shoulder abduction and elbow extension were 4/5 bilaterally, wrist dor-
siflexion was 1/5, finger extension and thumb abduction were 3/5, and finger 
flexion and abductor digiti minimi were 4/5, whereas shoulder adduction, elbow 
flexion and wrist flexion were 5/5 bilaterally. In the lower limbs, hip flexion was 
4/5 bilaterally, and ankle dorsiflexion, ankle plantar flexion, toe flexion and toe 
extension were 1/5, whereas hip abduction, hip adduction, knee flexion and 
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knee extension were 5/5 bilaterally. Deep tendon reflexes were absent in the 
upper limbs. The right knee jerk was 2+, and the left knee jerk was brisk (3+). 
Ankle jerks were absent and toes were mute on Babinski testing. There was loss 
of pinprick and temperature sensation to the mid-calf level bilaterally.
Patient V:7. A cousin of the proband (V:7, Fig. 1b) observed right leg weak-
ness at 33 years of age. Symptoms progressed to the point that the patient has 
been using a power wheelchair since 57, although continuing to walk slowly 
using a rollator walker as part of an exercise regimen. Hand weakness developed 
at age 60, and the subject had an episode of aspiration pneumonia requiring 
prolonged intubation and hospitalization at age 63. The patient has required 
nocturnal noninvasive ventilation and daytime oxygen supplementation since 
that time. Mild dysphagia and occasional choking episodes required changes 
in food consistency.
Neurological examination at age 65 revealed mild dysarthria, mild facial 
weakness and a brisk jaw jerk. Generalized limb atrophy and pyramidal- 
distribution weakness was evident. In the upper limbs, shoulder abduction, 
elbow flexion and elbow extension were 4/5 bilaterally, wrist extension was 3/5, 
finger extension was 4/5 and thumb abduction was 3/5, whereas shoulder 
adduction, wrist flexion and adductor digiti minimi were 5/5 bilaterally. In the 
lower limbs, hip flexion was 4/5 bilaterally, hip abduction and hip adduction 
were 3/5, knee flexion and knee extension were 1/5, ankle dorsiflexion and ankle 
plantar flexion were 0/5, and toe extension was 1/5 bilaterally. Deep tendon 
reflexes were absent in all four limbs, and toes were mute on Babinski testing. 
Temperature sensation was diminished to the mid-calf level bilaterally.
Patient V:8. A cousin of the proband (V:8, Fig. 1b) presented with dysarthria and 
choking at 47 years of age. The patient developed left ankle weakness at age 52. 
Weakness had spread to both hands by age 58. Currently, at age 63, the patient 
has difficulty using eating utensils and walks with the aid of a walker.
Neurological examination at age 63 revealed dysarthria with nasal air escape, 
poor palate elevation, tongue fasciculations and a brisk jaw jerk. There was marked 
distal atrophy and weakness. In the upper limbs, wrist extension was 4/5 bilater-
ally, finger extension and thumb abduction were 3/5, and left abductor digiti 
minimi was 4/5, whereas bilateral shoulder abduction, shoulder adduction, elbow 
flexion, elbow extension, wrist flexion and right adductor digiti minimi were 5/5. 
In the lower limbs, ankle dorsiflexion and ankle invertors were 3/5 bilaterally and 
extensor hallucis longus was 4/5, whereas hip flexion, hip extension, hip abduc-
tion, hip adduction, knee flexion, knee extension, ankle plantar flexion and foot 
evertors were 5/5 bilaterally. Triceps reflexes were brisk (3+) bilaterally, whereas 
other deep tendon reflexes in the upper limbs were normal (2+). Knee jerks were 
brisk (3+) bilaterally, ankle jerks were absent, and toes were mute on Babinski 
testing. Vibration sensation was diminished to the level of the ankles bilaterally.
Patient V:13. A cousin of the proband (V:13, Fig. 1b) noticed mild dysarthria and 
throat-clearing difficulties at 42 years of age. At age 44, the subject developed 
right leg weakness that spread to involve the left leg and both hands by age 51. 
The patient occasionally chokes when eating. Currently, at age 58, the patient 
remains mobile with the aid of bilateral ankle orthotics.
Neurological examination, at age 58, revealed trace dysarthria. There was 
prominent distal muscle atrophy. In the upper limbs, right shoulder abduction 
was 4/5 bilaterally and wrist extension and finger extension were 3/5, whereas 
shoulder adduction, elbow flexion, elbow extension, wrist flexion and finger 
flexion were 5/5 bilaterally. In the lower limbs, left hip flexion was 4/5, ankle 
dorsiflexion was 2/5 bilaterally and extensor hallucis longus was 3/5, whereas 
hip extension, hip abduction, hip adduction, knee flexion, knee extension and 
ankle plantar flexion were 5/5 bilaterally. In the upper limbs, reflexes were 
diminished (1+). In the lower limbs, knee jerks were brisk (3+ with crossed 
adductors), ankle jerks were absent, and the toes were mute on Babinski testing. 
All sensory modalities were intact.
Patient V:15. A cousin of the proband (V:15, Fig. 1b) developed hand weakness 
at 49 years of age. Currently, at age 50, the patient complains of fatigue, frequent 
cramping of the right foot, and mild dysarthria when fatigued.
Neurological examination, at age 50, revealed bilateral thenar and first dorsal 
interossei muscle atrophy. In the upper limbs, wrist extension, finger extension 
and thumb abduction were 4/5 bilaterally, whereas shoulder abduction, shoulder 
adduction, elbow flexion, elbow extension, wrist flexion and finger flexion were 
5/5 bilaterally. In the lower limbs, extensor hallucis longus was 4/5 bilaterally, 
whereas all other muscle groups were 5/5. Reflexes in the upper limbs were 
2+ with the exception of the left brachioradialis, which was diminished (1+). 
In the lower limbs, knee jerks were brisk (3+ with crossed adductors) bilaterally, 
ankle jerks were absent, and toes were downgoing on Babinski testing. Vibration 
sensation was diminished to the level of the ankle bilaterally. The patient had 
difficulty with heel walking and toe walking.
In summary, the clinical features of patients in the Ser85Cys MATR3 kindred 
were consistent with a progressive, fatal motor neuron disease with combined 
upper and lower motor neuron signs, bulbar dysfunction and respiratory failure.
description of the ItAlS#10 pedigree (thr622Ala). The proband (III:1, Fig. 1c) 
developed spinal ALS presenting with left foot drop at 62 years of age. MRI with 
diffusion tensor imaging revealed bilateral corticospinal tract damage. The patient 
was cognitively normal on exam, and [18F]fluorodeoxyglucose PET imaging was 
also reported to be normal. The patient remains alive 32 months after symptom 
onset and uses noninvasive ventilation for 12 h per day.
Patient III:3. A cousin of the proband (III:3, Fig. 1c) presented with a 5-month 
history of progressive right arm weakness at 60 years of age. Neurological exami-
nation at the time of presentation showed weakness and hypotrophy in upper 
limbs, more evident on the right side and in distal muscles. Deep tendon reflexes 
were diffusely brisk, especially on the right. MRIs of the brain and cervical spinal 
cord were normal. EMG showed active and chronic denervation in upper limbs 
muscles, whereas motor evoked potentials revealed increased central conduction 
time. Over the following months, the patient’s symptoms progressed to involve 
the lower limbs and respiratory muscles. She died 33 months after disease onset 
of respiratory failure.
No mutation in known ALS-associated genes, including the pathogenic repeat 
expansion of C9ORF72, segregated with disease in the ITALS#10 kindred.
description of the UkAlS#1 pedigree (Pro154Ser). The proband of the 
UKALS#1 family (II:1, Fig. 1d) was Indian and developed upper limb weakness 
at 59 years of age. There was no family history of ALS or dementia, though an 
offspring (III:I) was diagnosed with autism. Over the next 3 years, the patient’s 
symptoms spread to involve the remaining limbs and bulbar musculature. The 
patient now uses a wheelchair for mobility and requires ventilator support for 
respiratory failure, a gastrostomy tube for feeding and an eye-tracking system 
for communication. Neurological examination, at age 62, revealed widespread 
upper and lower motor neuron signs and bulbar involvement consistent with a 
diagnosis of ALS.
The affected member of UKALS#1 was negative for mutations in known ALS-
associated genes, including the pathogenic repeat expansion of C9ORF72.
Additional samples. For subsequent mutational screening, we examined exome 
sequence data that had been generated in our laboratory using DNA obtained 
from 108 individuals (n = 6 Canadians, n = 14 Germans, n = 9 Israelis, n = 32 
Italians, n = 47 from the United States) who had been diagnosed with familial 
ALS and who were negative for mutations in known ALS-associated genes, 
including the pathogenic hexanucleotide repeat expansion of C9ORF72. Average 
age of symptom onset among this cohort was 55.1 (range, 15.0–79.0), and 47.2% 
were male.
Multiethnic control samples consisted of a series of 1,051 anonymous samples 
that are part of the Human Gene Diversity Panel (http://www.cephb.fr/en/hgdp/
diversity.php/). These samples come from the following geographical regions: 
Africa (n = 122), Algeria (n = 30), Brazil (n = 45), Cambodia (n = 11), China 
(n = 182), Colombia (n = 13), France (n = 53), Israel (n = 144), Italy (n = 50), 
Japan (n = 30), Mexico (n = 50), New Guinea (n = 39), Orkney Islands (n = 16), 
Pakistan (n = 199) and Russia (n = 67).
Neurologically normal control subjects who were genotyped as part of 
the genome-wide association study that was ongoing in the Laboratory of 
Neurogenetics, NIA, consisted of samples from the United States (n = 2,882), 
the United Kingdom (n = 677), Italy (n = 1,242) and Finland (n = 389).
The appropriate institutional review board (National Institute on Aging 
Institutional Review Board protocol number 2003-081) approved the study, and 
informed consent was obtained from all subjects included in this study.
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exome sequencing and bioinformatic analysis pipeline. DNA from affected 
individuals II:7, III:1, III:10 and III:11 of the USALS#3 family was enriched using 
TruSeq technology (version 1.0) and paired-end sequenced on a Hiseq2000 
sequencer according to the manufacturer’s protocol (Illumina, San Diego, CA). 
This generated 8.0 gigabases (Gb) of alignable sequence data for individual II:7, 
15.4 Gb for III:1, 7.8 Gb for III:10 and 9.7 Gb for III:11 (mean 10× coverage = 
95.4%, range 94.3 to 98.0%; mean 30× coverage = 87.9%, range 85.1 to 93.1%). 
Exome sequence data from the additional 108 familial ALS samples were gener-
ated in a similar manner. Sample randomization was not performed and the 
researchers were not blinded to genotype. Statistical methods were not used to 
predetermine sample sizes, but rather our sample sizes were dictated by patient 
availability and are similar to those generally employed in the field.
Sequence alignment and variant calling were performed against the reference 
human genome (UCSC hg 19) using the Genome Analysis Toolkit (http://www.
broadinstitute.org/gatk/). PCR duplicates were removed before variant calling 
using Picard software (http://picard.sourceforge.net/index.shtml).
A series of standard filters was applied to the exome sequence data gener-
ated for the USALS#3 family to identify the causative mutation. First variants 
and indels that were not shared by all four affected members were excluded. 
Next variants and indels that were homozygous or nonautosomal were 
excluded. Then synonymous and noncoding changes were identified using 
the SeattleSeq online tool (annotation 137, http://snp.gs.washington.edu/
SeattleSeqAnnotation137/index.jsp) and filtered from the variant list. Under 
the hypothesis that the mutation underlying this rare familial disease was not 
present in the general population, SNPs identified in the Exome Sequencing 
Project (n = 6,500, http://evs.gs.washington.edu/, accessed 25 March 
2013), the 1000 Genomes project (n = 1,092, 20110521 release, version 3, 
http://www.1000genomes.org/, accessed 25 March 2013) or dbSNP (build 137, 
http://www.ncbi.nlm.nih.gov/SNP/, accessed 25 March 2013) were filtered. As 
an additional step, variants and indels detected in the USALS#3 family were 
filtered against exome data generated in our laboratory for 200 neurologically 
normal control subjects. Supplementary Figure 7 shows the number of variants 
filtered by each of these steps in the USALS#3 pedigree, and Supplementary 
Figure 8 shows the genomic location of the two novel coding variants identified 
by exome sequencing.
Sanger sequencing using customized primers was performed to confirm the 
presence of the two remaining variants.
Exome data for the 108 familial ALS cases was processed in an identical 
manner.
genotyping. Genotyping of the LMNB1 (chr5:126156748, C>T, Ala436Val, 
NM_005573.3) and MATR3 (chr5:138643448, T > G, Phe115Cys, NM_199189.2) 
variants was performed in the Human Gene Diversity Panel samples using 
Taqman SNP genotyping assays (Life Technologies Corp., Grand Island, NY, 
USA) on the 7900HT Fast Real Time PCR System according to the manufacturer’s 
instructions (Applied Biosystems Inc., Foster City, CA, USA).
The MATR3 chr5:138643448, T > G (Phe115Cys) and chr5:138643358, C>G 
(Ser85Cys) variants were assayed in an additional 5,190 neurologically normal 
control subjects of European ancestry as part of a genome-wide association 
project that was ongoing in the Laboratory of Neurogenetics, NIA, using the 
HumanExome+ SNP chip with custom content (Illumina).
Immunohistochemistry of spinal cord. Immunohistochemistry was performed 
on lumbar spinal cord from ALS patients (n = 16), neurologically normal controls 
(n = 6) and one ALS patient with the Phe115Cys MATR3 mutation as follows: 
tissues were deparaffinized, rehydrated and subjected to antigen retrieval for 
20 min in a steamer in pH 9 buffer (Dako Inc., Carpinteria, CA, USA) for the 
Sigma antibody, and in pH 6 citrate buffer (BioGenex Inc., Freemont, CA, USA) 
for the Abcam antibody. This was followed by 20 min incubation in buffer warmed 
to 100 °C. Next, slides were blocked in Superblock (ScyTek Laboratories Inc., West 
Logan, UT, USA) with avidin protein (Vector Laboratories Inc., Burlingame, 
CA, USA) for 1 h, after which primary antibody diluted in Superblock (Pierce 
Biotechnology, Rockford, IL, USA) with biotin (Vector Laboratories) was added 
for a second hour, with PBS washes in between. Slides were then incubated in 
biotinylated horseradish peroxidase (HRP)-conjugated secondary antibody 
(catalog number B-2004, 1:200 dilution, Vector Laboratories). The primary 
anti-MATR3 antibodies were HPA036565 (1:500 dilution, Sigma-Aldrich Corp., 
St. Louis, MO, USA) and ab151714 (1:500 dilution, Abcam PLC, Cambridge, 
MA, USA) (see Supplementary Fig. 9 for characterization of these antibodies). 
Slides were incubated with Vectastain Elite ABC reagent (Vector Laboratories) 
for 30 min, washed in PBS, and developed for 5 min using Vector NovaRED 
Substrate Kit (Vector Laboratories). Finally, slides were counterstained with 
Mayer’s hematoxylin (Sigma-Aldrich) for 1 min, dehydrated, and mounted in 
Permount medium.
All pictures were taken with an Olympus BX40 light microscope, and 
images were acquired using a Nikon DS L2 digital camera. Image analysis was 
performed with Photoshop CS5 (Adobe Systems Inc., San Jose, CA, USA). 
All of the samples shown in Figure 2 and Supplementary Figures 2 and 3  
were processed at the same time.
Immunohistochemistry of skeletal muscle. Cryostat sections of rapidly fro-
zen skeletal muscle were processed in a standard fashion consistent with ref. 17. 
Immunocytochemistry for each antibody was performed on tissue from 
patients and compared with normal tissue controls processed simultaneously 
(Supplementary Fig. 6). Primary antibodies used in this study were TDP-43 
rabbit polyclonal antibody (catalog number 10782-2-AP, ProteinTech Antibody 
Group, Chicago, Illinois, USA) and MATR3 mouse monoclonal (catalog number 
sc-81318, Santa Cruz, Santa Cruz, CA). Dilutions were both 1:1,000. Double-
labeling immunofluorescence was performed as previously described using sec-
ondary antibodies conjugated to Alexa Fluor 488 and 594 (Invitrogen, catalog 
numbers A-21200 and A-21442, 1:200 dilution). Sections were examined using 
a fluorescence microscope (80i upright; Nikon) and charge-coupled device cam-
era (EZ monochrome; Roper Industries) with deconvolution software analysis 
(NIS Elements; Nikon). Image processing and analysis were performed with NIS 
Elements 4.0 software and Photoshop CS3 (Adobe Systems Inc.).
Immunoprecipitation. Mutations (Ser85Cys, Phe115Cys and Thr622Ala) were 
introduced into Flag-tagged MATR3 cDNA plasmid (Addgene, Cambridge, 
MA, USA) using a QuikChange II XL Site-Directed Mutagenesis Kit (Agilent 
Technologies Inc., Santa Clara, CA, USA). All plasmids were sequence-verified. 
For Flag immunoprecipitation of MATR3, HEK293FT cells (Life Technologies 
Corp., Grand Island, NY, USA) transiently expressing Flag-MATR3 were lysed 
with lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1mM EDTA, 0.5% 
(v/v) NP-40, phosphatase (Thermo Scientific, number 78427) and protease 
inhibitor (Roche, catalog number 04693159001) for 30 min at 4 °C. Lysate 
was precleared with EZview Red Protein G Affinity Gel (Sigma-Aldrich) for 
30 min at 4 °C, followed by immunopurification with EZview Red Anti-Flag M2 
Affinity Gel (catalog number F2426, Sigma-Aldrich) for 2 h at 4 °C. Protein-gel 
complexes were washed four times with lysis buffer. MATR3 was eluted using 
Gentle Ag/Ab Elution Buffer (Thermo Fisher Scientific Inc., Rockford, IL, USA) 
for 30 min at room temperature.
Protein samples were prepared for SDS-PAGE in SDS sample buffer (Life 
Technologies) and boiled at 95 °C for 10 min before electrophoresis on 4–20% 
TGX gels (Bio-Rad Laboratories Inc., Hercules, CA, USA). Proteins were trans-
ferred to PVDF membranes using the semi-dry Trans-Blot Turbo Transfer 
System (Bio-Rad). Membranes were blocked with 5% non-fat milk OmniBlok 
(American Bioanalytical Inc., Natick, MA, USA). The following primary anti-
bodies were used at the indicated dilutions: rabbit anti-MATR3 ab151714 (1:200, 
Abcam), rabbit anti-MATR3 HPA036564 (1:200, Sigma-Aldrich), mouse anti-
Flag F1804 (1:5,000, Sigma-Aldrich), rabbit anti-TDP43 10782-2-AP (1:2,000, 
ProteinTech Group Inc., Chicago, IL, USA) and rabbit anti-DHX9 A300-855A 
(1:2,000, Bethyl Laboratories Inc., Montgomery, TX, USA). Immunoreactivity 
was revealed using appropriate HRP-conjugated secondary antibodies (1:5,000, 
Jackson ImmunoResearch Laboratories Inc., West Grove, PA, USA, catalog 
numbers 711-035-1521 and 715-035-1501) and the ECL Plus chemiluminescent 
system (Pierce). Quantitation was performed using ImageJ software (version 
1.41, National Institutes of Health, USA). Wilcoxon signed-rank test was used to 
estimate significance for differences in median values of interaction of MATR3 
with TDP-43 and DHX9, comparing the values relative to wild-type protein in 
each experiment.
17. Weihl, C.C. et al. J. Neurol. Neurosurg. Psychiatry 79, 1186–1189 (2008).
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